Roche Holding and Merck have agreed to partner on a companion diagnostic test to identify patients eligible to receive Merck's anti-PD-1 therapy Keytruda. The immunohistochemistry test will evaluate mismatch repair deficiency in solid tumors by detecting four MMR proteins.
Roche signs companion Dx development deal with Merck
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.